Regeneron (REGN) Misses Q1 EPS by 64c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron Pharma (REGN) PT Lowered to $1,185 at RBC Capital
May 3, 2024 6:46 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,185.00 (from $1,189.00) while maintaining a Outperform rating.
The analyst comments "Overall, a reasonably solid quarter, with Eylea HD looking good, Eylea 2mg missing probably to a... More
Regeneron (REGN) misses earnings, revenue expectations
May 2, 2024 7:05 AM EDTRegeneron (NASDAQ: REGN) experienced a slight decline in its stock price, falling 1.82% after reporting first-quarter earnings and revenue that fell short of Wall Street expectations. The biotechnology company announced an adjusted EPS of $9.55, which was below the analyst estimate of $10.19. Revenue for the quarter was $3.15 billion, also missing the consensus estimate of $3.22 billion.
Despite the overall revenue decrease of 1% from the same quarter last year, the company highlighted a 7% increase when excluding sales from Ronapreve, a COVID-19 treatment. Notably,... More
